Palisade Bio Inc (PALI)

$2.14 +0.27 (14.44%)
Market Cap 303.97M
Revenue (ttm) 0.00
Net Income (ttm) -14.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.12
Volume 5,508,936
Avg Vol 9,202,518
Day's Range N/A - N/A
Shares Out 149.00M
Stochastic %K 64%
Beta 1.60
Analysts Strong Sell
Price Target $10.33

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement wi...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4900
Address:
7750 El Camino Real, Suite 2A, Carlsbad, United States
RandomInvestor777
RandomInvestor777 Nov. 14 at 10:30 PM
$PALI this is a very long term investment. their pipeline is all at phase 1. with huge risk of binaries
0 · Reply
Easy_Trades
Easy_Trades Nov. 14 at 8:57 PM
$PALI - adding here at buy signal . With tight stop
0 · Reply
biochirp
biochirp Nov. 14 at 7:37 PM
$PALI probably hits 6$ on $ABVX BO
0 · Reply
topstockalerts
topstockalerts Nov. 14 at 7:32 PM
$PALI Looking good!
0 · Reply
Momo7002momo
Momo7002momo Nov. 14 at 7:30 PM
$PALI $WGRX $BNAI raising from the dead
0 · Reply
SimSimBola
SimSimBola Nov. 14 at 7:25 PM
$PALI this dog refuses to die!
0 · Reply
FE123
FE123 Nov. 14 at 7:10 PM
$PALI Next $ABVX
0 · Reply
FE123
FE123 Nov. 14 at 6:54 PM
$APLD $PALI $TENX lets Go!!
0 · Reply
FE123
FE123 Nov. 14 at 6:53 PM
$IOVA $PALI $TENX Squeeeeze!!
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 6:35 PM
$PALI removing SNCA from your vault
0 · Reply
Latest News on PALI
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Oct 28, 2025, 8:45 AM EDT - 17 days ago

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Oct 20, 2025, 8:45 AM EDT - 25 days ago

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Oct 13, 2025, 8:45 AM EDT - 4 weeks ago

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Oct 9, 2025, 5:00 PM EDT - 5 weeks ago

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Oct 2, 2025, 4:05 PM EDT - 6 weeks ago

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Oct 1, 2025, 9:20 AM EDT - 6 weeks ago

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Sep 26, 2025, 4:05 PM EDT - 7 weeks ago

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Sep 17, 2025, 9:00 AM EDT - 2 months ago

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Sep 5, 2025, 8:45 AM EDT - 2 months ago

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Aug 25, 2025, 9:00 AM EDT - 2 months ago

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Aug 7, 2025, 9:15 AM EDT - 3 months ago

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Jul 31, 2025, 8:45 AM EDT - 3 months ago

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Jul 23, 2025, 8:00 PM EDT - 4 months ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 4 months ago

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Jul 9, 2025, 8:45 AM EDT - 4 months ago

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 27, 2025, 8:30 AM EDT - 6 months ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 6, 2025, 8:30 AM EDT - 6 months ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

May 1, 2025, 8:30 AM EDT - 7 months ago

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Apr 9, 2025, 8:30 AM EDT - 7 months ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Mar 14, 2025, 8:30 AM EDT - 8 months ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Mar 12, 2025, 8:30 AM EDT - 8 months ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Mar 4, 2025, 8:30 AM EST - 9 months ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Feb 20, 2025, 8:45 AM EST - 9 months ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 9 months ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Feb 10, 2025, 8:45 AM EST - 9 months ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Jan 29, 2025, 8:45 AM EST - 10 months ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 5:20 PM EST - 11 months ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Dec 17, 2024, 8:30 AM EST - 11 months ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 13, 2024, 4:05 PM EST - 1 year ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

What's Going On With Palisade Bio Stock On Thursday?

Dec 12, 2024, 12:55 PM EST - 1 year ago

What's Going On With Palisade Bio Stock On Thursday?

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 12, 2024, 12:05 PM EST - 1 year ago

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Dec 3, 2024, 8:15 AM EST - 1 year ago

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Nov 21, 2024, 8:15 AM EST - 1 year ago

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Nov 12, 2024, 8:45 AM EST - 1 year ago

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Jul 31, 2024, 9:15 AM EDT - 1 year ago

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Jul 19, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Jun 24, 2024, 9:00 AM EDT - 1 year ago

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

Jun 21, 2024, 8:15 AM EDT - 1 year ago

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

Jun 11, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

Palisade Bio to Present at the Virtual Investor Pitch Conference

Jun 10, 2024, 9:15 AM EDT - 1 year ago

Palisade Bio to Present at the Virtual Investor Pitch Conference

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

May 21, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 8:05 AM EDT - 1 year ago

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Palisade Bio Appoints Margery Fischbein to its Board of Directors

May 7, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Appoints Margery Fischbein to its Board of Directors

RandomInvestor777
RandomInvestor777 Nov. 14 at 10:30 PM
$PALI this is a very long term investment. their pipeline is all at phase 1. with huge risk of binaries
0 · Reply
Easy_Trades
Easy_Trades Nov. 14 at 8:57 PM
$PALI - adding here at buy signal . With tight stop
0 · Reply
biochirp
biochirp Nov. 14 at 7:37 PM
$PALI probably hits 6$ on $ABVX BO
0 · Reply
topstockalerts
topstockalerts Nov. 14 at 7:32 PM
$PALI Looking good!
0 · Reply
Momo7002momo
Momo7002momo Nov. 14 at 7:30 PM
$PALI $WGRX $BNAI raising from the dead
0 · Reply
SimSimBola
SimSimBola Nov. 14 at 7:25 PM
$PALI this dog refuses to die!
0 · Reply
FE123
FE123 Nov. 14 at 7:10 PM
$PALI Next $ABVX
0 · Reply
FE123
FE123 Nov. 14 at 6:54 PM
$APLD $PALI $TENX lets Go!!
0 · Reply
FE123
FE123 Nov. 14 at 6:53 PM
$IOVA $PALI $TENX Squeeeeze!!
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 6:35 PM
$PALI removing SNCA from your vault
0 · Reply
bowlerhatsftw
bowlerhatsftw Nov. 14 at 5:38 PM
$PALI 20 day high
0 · Reply
TradeHuntFish
TradeHuntFish Nov. 13 at 6:51 PM
$TRUG looks like a misprint. A 2 million MARKET cap with a float this tiny and a $2M buyback locked in? That’s the kind of structural setup that sparks violent re rates when the market wakes up. Microcaps this tight don’t stay cheap. $RELI $PALI $POLA $NVVE
0 · Reply
ignoreo
ignoreo Nov. 12 at 8:00 PM
$PALI i hate it when stocks i own go up 10%+ without news in a flat/down market, even if i believe they are worth 500% more than theyre trading at
0 · Reply
d_risk
d_risk Nov. 10 at 11:44 PM
$PALI - PALISADE BIO, INC. - 10Q - Updated Risk Factors PALI’s latest 10-Q risk factors spotlight new threats: Nasdaq delisting risk, expanded financial and IP risks, heavy dependence on third parties, major hurdles for PALI-2108’s clinical and regulatory path, ongoing net losses, material internal control weaknesses, vulnerability to government shutdowns, cybersecurity threats, and heightened exposure to market volatility and dilution. #Biotechnology #Cybersecurity #FinancialRisk #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/PALI/10-Q/2025-11-10
0 · Reply
TwongStocks
TwongStocks Nov. 10 at 9:22 PM
$PALI 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1357459/000119312525274262/pali-20250930.htm
0 · Reply
autographic
autographic Nov. 7 at 6:21 PM
$PALI Looking good 😊
0 · Reply
autographic
autographic Nov. 7 at 3:39 PM
$PALI Added some trading shares - thesis : will trade higher as UC drug mechanism gains popularity imo. Risk
0 · Reply
BanditQ
BanditQ Nov. 5 at 8:02 PM
$PALI TRASHH, BUY $EQ INSTEAD!!!
1 · Reply
biochirp
biochirp Nov. 5 at 6:31 PM
$PALI good time to get back in
1 · Reply
Kyle7776
Kyle7776 Nov. 5 at 7:00 AM
$PALI dilution
0 · Reply
NikkosBelfort
NikkosBelfort Nov. 4 at 4:52 PM
$PALI pos
0 · Reply
autographic
autographic Nov. 4 at 4:37 PM
$PALI 🚨 Back in Pali - prior support range .
0 · Reply